tickrz reports
  
tickrz rank
D
Celgene Corp (CELG)
Healthcare | Biotechnology
CEO: Mark J. Alles
Employees: 6971
celgene.com
FACTOR RANKINGSFACTOR SCREENER 
Pure Value Rank467Dividend RankNO DIVIDEND
Moat Rank42Financial Strength Rank146
Growth Rank81Momentum Rank169
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
VALUATION RATIOS
P/E Ratio44.28x
P/B Ratio12.39x
P/S Ratio8.11x
EV/EBITDA Ratio29.23x
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity187%
Interest Coverage5.83x
MOAT
ROE33.64%
ROIC21.2%
Net Margin18.3%
GROWTH
5 yr EPS Growth11.81%
5 yr SPS Growth17.67%
5 yr BPS Growth6.11%
Celgene Corp 's strong growth translates to a Growth Rank in the top 25% of all stocks
 tickrz summary
Celgene Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.
 value
 pure value ranking Warren Buffett ranking
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Celgene Corp's valuation score is comprised of a P/E ratio of 44.3x, a P/B ratio of 12.4x, a P/S ratio of 8.1x, and an EV/EBITDA ratio of 29.2x. Celgene Corp ranks 467 out of the S&P 500 constituents on valuation--a relatively weak score.Celgene Corp ranks 343 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Celgene Corp is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

 quality
 moat financial strength
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Celgene Corp appears to have a durable competitive advantage within the Healthcare sector. Celgene Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.83x, a debt/equity ratio of 187% and a Moat Rank of 42 translate to a strong Financial Strength score.


 momentum
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 18.36% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 169. Based on its 12 month stock performance, Celgene Corp will not appeal to momentum investors.

 yield
 value + yield
Celgene Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

 growth
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 11.8% 5 year annualized EPS growth, 17.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 6.1% speak to its impressive growth ranking.

Celgene Corp (CELG)
Healthcare | Biotechnology
CEO: Mark J. Alles
Employees: 6971
celgene.com


tickrz rank
D

VALUATION RATIOS
P/E Ratio44.28x
P/B Ratio12.39x
P/S Ratio8.11x
EV/EBITDA Ratio29.23x
DIVIDEND ANALYSIS
Dividend Yield0%
Payout RatioN/A
3 yr Dividend GrowthN/A
FINANCIAL STRENGTH
Piotroski F-Score7
Debt-to-Equity187%
Interest Coverage5.83x
MOAT
ROE33.64%
ROIC21.2%
Net Margin18.3%
GROWTH
5 yr EPS Growth11.81%
5 yr SPS Growth17.67%
5 yr BPS Growth6.11%

TICKRZ RANK
Celgene Corp receives a D ranking in our proprietary ranking system that combines valuation, moat, operational performance, and financial strength. View the Top 50 tickrz ranked stocks here.

PURE VALUE
Valuation is the most heavily weighted component in our tickrz ranking methodology. Numerous academic and practitioner studies have found that a value approach outperforms the market over the long-run. Celgene Corp's valuation score is comprised of a P/E ratio of 44.3x, a P/B ratio of 12.4x, a P/S ratio of 8.1x, and an EV/EBITDA ratio of 29.2x. Celgene Corp ranks 467 out of the S&P 500 constituents on valuation--a relatively weak score.

WARREN BUFFETT RANKING
Celgene Corp ranks 343 out of the S&P 500 constituents in our multi-factor Warren Buffett ranking methodology. This is a weak score, meaning it ranks poorly on valuation, moat, volatility, and financial strength factors. If you're looking for undervalued stocks with high moats and strong competitive advantages, Celgene Corp is probably not for you. However, the company's moat is strong so it could be worth investigating in the future should its valuation improve.

MOAT
To calculate a company's Moat Score, we look at its historical earnings growth, historical average return on equity, the volatility of its earnings stream, and also factor in the strength of its balance sheet. Our approach concludes the company's business moat is strong. Celgene Corp appears to have a durable competitive advantage within the Healthcare sector.

FINANCIAL STRENGTH
Celgene Corp has a Piotroski F Score of 7 out of 9. The F Score examines changes in profitability, leverage, liquidity, and operating efficiency. Interest coverage of 5.83x, a debt/equity ratio of 187% and a Moat Rank of 42 translate to a strong Financial Strength score.

MOMENTUM
Investment research has shown that stocks with strong performance over the last 6 to 12 months tend to perform better in the medium term than stocks with poor performance over the same period. In fact, the momentum factor is one of the strongest of all the investment factors. The company has seen its stock appreciate by 18.36% over the last 12 months. This performance is average compared to other stocks in the S&P 500, earning it a rank of 169. Based on its 12 month stock performance, Celgene Corp will not appeal to momentum investors.

VALUE + YIELD
Celgene Corp currently does not pay a dividend so it ranks last among S&P 500 companies using our dividend ranking methodology. Investors looking for undervalued dividend stocks will probably want to look elsewhere.

GROWTH
A company's growth metrics are less important than its valuation, moat, and financial strength. However, a check on growth can be a good way to avoid companies in secular decline. The company's growth in sales, earnings, and book value places it among the top third of S&P 500 companies. Its 11.8% 5 year annualized EPS growth, 17.7% 5 year annualized sales-per-share growth, and 5 year annualized book value-per-share growth of 6.1% speak to its impressive growth ranking.